Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gore

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
Science Signaling|March 27, 2014
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signalingBerta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, et al.
Cancer Treatment Reviews|June 22, 2011
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapiesBernard Escudier, Susanne Osanto, Börje Ljungberg, et al.
Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.
Gynecologic Oncology|April 23, 2016
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancerJosep María Del Campo, Michael Birrer, Craig Davis, et al.
Nature Genetics|April 28, 2012
Germline RAD51C mutations confer susceptibility to ovarian cancerChey Loveday, Clare Turnbull, Elise Ruark, et al.
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 16, 2019
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitorsAine O'Reilly, Peta Hughes, Jasmine Mann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma GroupUlrich Keilholz, Cornelis J A Punt, Martin Gore, et al.
Thrombosis Research|December 15, 2015
Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic casesOwen Mortimer Heath, Heleen J van Beekhuizen, Vivek Nama, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
Science Signaling|March 27, 2014
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signalingBerta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, et al.
Cancer Treatment Reviews|June 22, 2011
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapiesBernard Escudier, Susanne Osanto, Börje Ljungberg, et al.
Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.
Gynecologic Oncology|April 23, 2016
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancerJosep María Del Campo, Michael Birrer, Craig Davis, et al.
Nature Genetics|April 28, 2012
Germline RAD51C mutations confer susceptibility to ovarian cancerChey Loveday, Clare Turnbull, Elise Ruark, et al.
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 16, 2019
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitorsAine O'Reilly, Peta Hughes, Jasmine Mann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma GroupUlrich Keilholz, Cornelis J A Punt, Martin Gore, et al.
Thrombosis Research|December 15, 2015
Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic casesOwen Mortimer Heath, Heleen J van Beekhuizen, Vivek Nama, et al.
Pageof 14